MarkMonitor sees 23% growth in offshore business exchanges for bulk pharmaceuticals and APIs
Although the entry of counterfeit products into legitimate pharmaceutical distribution appear to remain limited, there is noticeable growth in trade in bulk products and APIs, according to the latest Brandjacking Index, compiled by MarkMonitor (San Francisco). These products become available to consumers who patronize illicit online pharmacies, and based on some rules of thumb of e-commerce, MarkMonitor estimates that the volume of such sales has reached $11 billion, up form $4 billion in 2007, the first time MarkMonitor performed its study.
MarkMonitor tracks online activity in pharmaceutical e-commerce (and other branded products subject to counterfeiting) by using proprietary algorithms to uncover instances of “cybersquatting”—improper use of brandnames in Internet domains. By following six leading pharmaceutical brandnames, it found 20,000 instances of cybersquatting, including 652 exchanges—up 67% from 2007. By analyzing the volumes available for sale and public records of online traffic, it can derive estimates of the online sources and volume of such trade.
Other results from the study, conducted during the past summer:
“Scammers are opportunists, and by targeting the supply chain they’re positioning themselves to move the greatest amount of fake product they can,” said Frederick Felman, chief marketing officer at MarkMonitor. “This maximizes their return on the scam but it also poses a potential danger to peoples’ health and safety, not to mention brand reputation.” The company provides “enterprise brand protection” services to brand owners through its online monitoring services.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.